Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Financials | Market Cap | ROE | ROA | ROCE | ROIC | D/E | Current Ratio | Gross Margin | Profit Margin | Operating Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARGX | ARGENX SE | $35.11B | 17.40% | 15.50% | 1.58% | 3.00% | 0.13 | 7.29 | -5,127.40% | 19,159.20% | 2,015.73% | ||
| CRMD | CORMEDIX INC | $987.53M | 22.60% | 17.00% | 14.95% | 53.00% | 0.30 | 4.21 | 95.20% | 20.80% | 20.85% | ||
| GYRE | GYRE THERAPEUTICS INC | $749.12M | 11.40% | 5.80% | 9.86% | 11.80% | 0.37 | 3.60 | 96.20% | 7.20% | 10.86% | ||
| TGTX | TG THERAPEUTICS INC | $5.72B | 18.90% | 7.00% | 14.17% | 14.00% | 1.77 | 4.02 | 87.40% | 10.10% | 18.21% | ||
| CORT | CORCEPT THERAPEUTICS INC | $7.43B | 20.40% | 16.60% | 15.55% | 19.70% | 0.24 | 3.07 | 98.40% | 19.30% | 15.95% | ||
| RPRX | ROYALTY PHARMA PLC | $19.59B | 10.90% | 6.10% | 8.15% | 5.70% | 0.80 | 1.56 | 100.00% | 48.30% | 59.15% | ||
| VCEL | VERICEL CORP | $2.15B | 1.10% | 0.70% | 0.97% | 1.00% | 0.44 | 5.01 | 72.50% | 1.20% | 1.57% | ||
| KRYS | KRYSTAL BIOTECH INC | $3.96B | 13.60% | 12.30% | 13.87% | 23.50% | 0.09 | 9.65 | 93.20% | 37.20% | 41.39% | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.11B | 10.80% | 7.50% | 10.64% | 9.80% | 0.44 | 5.93 | 88.20% | 16.10% | 18.77% | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.89B | 24.30% | 15.90% | 24.31% | 47.70% | 0.47 | 3.67 | 78.30% | 20.50% | 28.73% | ||
| HALO | HALOZYME THERAPEUTICS INC | $6.65B | 122.20% | 23.30% | 30.45% | 25.20% | 3.56 | 8.39 | 83.40% | 44.80% | 57.46% | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.87B | 28.30% | 24.40% | 32.42% | 400.20% | 0.14 | 6.14 | 86.10% | 36.90% | 48.34% | ||
| INCY | INCYTE CORP | $13.11B | 0.60% | 0.40% | 7.87% | 16.30% | 0.57 | 2.04 | 92.70% | 0.50% | 7.19% | ||
| ADMA | ADMA BIOLOGICS INC | $4.97B | 72.40% | 46.80% | 33.45% | 38.60% | 0.37 | 6.58 | 52.60% | 45.00% | 33.28% | ||
| MNKD | MANNKIND CORP | $1.13B | -21.00% | 7.00% | 24.67% | 11.10% | -8.00 | 2.36 | 74.60% | 10.10% | 24.39% | ||
| EXEL | EXELIXIS INC | $11.34B | 29.40% | 22.30% | 34.37% | 34.80% | 0.33 | 3.50 | 96.80% | 28.00% | 36.45% | ||
| NVO | NOVO NORDISK A S | $356.44B | 81.20% | 24.30% | 52.29% | 74.30% | 2.53 | 0.74 | 84.30% | 34.50% | 43.65% | ||
| MDXG | MIMEDX GROUP INC | $892.12M | 21.60% | 15.90% | 23.50% | 50.80% | 0.33 | 4.70 | 81.90% | 11.40% | 15.19% | ||
| TECH | BIO-TECHNE CORP | $7.92B | 6.30% | 4.90% | 7.22% | 13.40% | 0.31 | 3.71 | 65.80% | 10.90% | 14.79% | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.69B | 11.90% | 4.10% | 5.69% | 7.50% | 1.76 | 3.38 | 88.80% | 11.90% | 14.44% | ||
| VCYT | VERACYTE INC | $2.07B | 2.80% | 2.60% | 2.83% | 23.70% | 0.10 | 5.10 | 68.00% | 7.10% | 7.57% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.78B | 9.50% | 7.50% | 10.53% | 12.20% | 0.23 | 5.52 | 79.40% | 17.80% | 23.26% | ||
| NAGE | NIAGEN BIOSCIENCE INC | $1.07B | 33.90% | 21.70% | 24.10% | 162.20% | 0.47 | 3.66 | 62.50% | 13.10% | 13.51% | ||
| GMAB | GENMAB A | $15.11B | 23.00% | 18.50% | 27.34% | 70.10% | 0.24 | 5.34 | 95.10% | 35.20% | 50.62% | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.63B | 35.30% | 21.70% | 31.92% | 64.00% | 0.48 | 2.88 | 92.00% | 23.00% | 26.58% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.